Trial Type: Liver

BRUOG-430
A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
Protocol Status: OPEN TO ACCRUAL
Contact: Raufi, Alexander